Deutsch English Français

Contact

EP2460530

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2460530

EP2460530 - Human growth hormone crystals and methods for preparing them [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 28.08.2015 Database last updated on 28.09.2024
Most recent event Tooltip	28.08.2015	Application deemed to be withdrawn	published on 30.09.2015 [2015/40]
Applicant(s)	For all designated states Althea Technologies, Inc. 11040 Roselle Street San Diego, CA 92121 / US
	[2012/23]
Inventor(s)	01 / Govardhan, Chandrika 9 Scotland Road Lexington, MA 02420 / US
	02 / Khalaf, Nazer 14 Lauf Street Worcester, MA 01602 / US
	03 / Simeone, Benjamin Paul 1798 Massachusetts Avenue Lexington, MA 02420 / US
	[2012/23]
Representative(s)	Graf von Stosch, Andreas Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstraße 22 80538 München / DE
	[N/P]
Former [2012/23]	Graf von Stosch, Andreas Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22 80538 München / DE
Application number, filing date	11168985.7	31.12.2003
	[2012/23]
Priority number, date	US20020437519P	31.12.2002 Original published format: US 437519 P
	US20030517042P	03.11.2003 Original published format: US 517042 P
	[2012/23]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2460530
	Date:	06.06.2012
	Language:	EN
	[2012/23]
	Type:	A3 Search report
	No.:	EP2460530
	Date:	29.08.2012
	Language:	EN
	[2012/35]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	27.07.2012
Classification	IPC:	A61K38/27, C07K14/61	[2012/23]
	CPC:	C07K14/61 (EP,KR,US); A61K38/27 (KR); A61P1/00 (EP); A61P1/04 (EP); A61P13/12 (EP); A61P15/08 (EP); (+) A61P17/02 (EP); A61P19/08 (EP); A61P31/18 (EP); A61P5/06 (EP); A61K38/00 (EP,US); A61K9/0019 (EP,US); C07K2299/00 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2012/23]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
Title	German:	Kristalle des menschlichen Wachstumshormons und Verfahren zu ihrer Herstellung	[2012/23]
	English:	Human growth hormone crystals and methods for preparing them	[2012/23]
	French:	Cristaux d'hormone de croissance humaine et leurs procédés de préparation	[2012/23]
Examination procedure	28.02.2013	Amendment by applicant (claims and/or description)
	28.02.2013	Examination requested [2013/15]
	16.04.2013	Despatch of a communication from the examining division (Time limit: M04)
	14.08.2013	Reply to a communication from the examining division
	08.10.2014	Despatch of a communication from the examining division (Time limit: M06)
	21.04.2015	Application deemed to be withdrawn, date of legal effect [2015/40]
	21.05.2015	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2015/40]
Parent application(s) Tooltip	EP03808602.1 / EP1581251
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030808602) is 29.05.2009
Fees paid	Renewal fee
	06.10.2011	Renewal fee patent year 03
	06.10.2011	Renewal fee patent year 04
	06.10.2011	Renewal fee patent year 05
	06.10.2011	Renewal fee patent year 06
	06.10.2011	Renewal fee patent year 07
	06.10.2011	Renewal fee patent year 08
	27.12.2011	Renewal fee patent year 09
	26.12.2012	Renewal fee patent year 10
	27.12.2013	Renewal fee patent year 11
	Penalty fee
	Additional fee for renewal fee
	31.12.2014	12 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]EP1073421 (ALTUS BIOLOGICS INC [US]) [X] 1-3,5-14,18 * claims 38-43 *;
		[X]WO02053174 (PBL BIOMEDICAL LAB [US], et al) [X] 15-17 * claims 3, 12-14 *
		[A] - JEN A ET AL, "Diamonds in the rough: Protein crystals from a formulation perspective", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, (20011101), vol. 18, no. 11, ISSN 0724-8741, pages 1483 - 1488, XP002307178 [A] 1-14,18 * the whole document * DOI: http://dx.doi.org/10.1023/A:1013057825942
		[X] - CLELAND J L ET AL, "STABLE FORMULATIONS OF RECOMBINANT HUMAN GROWTH HORMONE AND INTERFERON-GAMMA FOR MICROENCAPSULATION IN BIODEGRADABLE MICROSPHERES", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, (19960101), vol. 13, no. 10, ISSN 0724-8741, pages 1464 - 1475, XP001084606 [X] 1-14,18 * the whole document * DOI: http://dx.doi.org/10.1023/A:1016063109373
		[T] - GOVARDHAN CHANDRIKA ET AL, "Novel long-acting crystal formulation of human growth hormone", PHARMACEUTICAL RESEARCH (DORDRECHT), (200509), vol. 22, no. 9, ISSN 0724-8741, pages 1461 - 1470, XP002509313 [T] 1-14,18 DOI: http://dx.doi.org/10.1007/s11095-05-6021-x
		[A] - TAI I T ET AL, "MICROENCAPSULATION OF RECOMBINANT CELLS: A NEW DELIVERY SYSTEM FOR GENE THERAPY", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, US, (19930101), vol. 7, ISSN 0892-6638, pages 1061 - 1069, XP002016275 [A] 1-14,18 * the whole document *
	by applicant	US5981485
		US6448225
		US5780599
		US6117984
		US4342832
		US5633352
		- MAURAS ET AL., J. CLIN. ENDOCRINOLOGY AND METABOLISM, (2000), vol. 85, no. 10, pages 3653 - 3660
		- FRINDIK ET AL., HORMONE RESEARCH, (1999), vol. 51, no. 1, pages 15 - 19
		- LEGER ET AL., J. CLIN. ENDOCRINOLOGY AND METABOLISM, (1998), vol. 83, no. 10, pages 3512 - 3516
		- BRAMSWIG, ENDOCRINE, (2001), vol. 15, no. 1, pages 5 - 13
		- PASQUINO ET AL., HORMONE RESEARCH, (1996), vol. 46, no. 6, pages 269 - 272
		- CARROLL ET AL., TRENDS IN ENDOCRINOLOGY AND METABOLISM, (2000), vol. 11, no. 6, pages 231 - 238
		- UELAND ET AL., J. CLIN. ENDOCRINOLOGY AND METABOLISM, (2002), vol. 87, no. 6, pages 2760 - 2763
		- SIMPSON ET AL., GROWTH HORMONE & IGF RESEARCH, (2002), vol. 12, pages 1 - 33
		- MEHLS, HAAS, GROWTH HORMONE & IGF RESEARCH, (2000), pages S31 - S37
		- FINE ET AL., J. PEDIATRICS, (2000), vol. 136, no. 3, pages 376 - 382
		- MOTOYAMA ET AL., CLIN. EXP. NEPHROLOGY, (1998), vol. 2, no. 2, pages 162 - 165
		- HIRSCHFELD, HORMONE RESEARCH, (1996), vol. 46, pages 215 - 221
		- TRITOS ET AL., AM. J. MEDICINE, (1998), vol. 105, no. 1, pages 44 - 57
		- MULLIGAN ET AL., J. PARENTERAL AND ENTERAL NUTRITION, (1999), vol. 23, no. 6, pages 5202 - S209
		- TORRES, CADMAN, BIODRUGS, (2000), vol. 14, no. 2, pages 83 - 91
		- RITZEN, HORMONE RESEARCH, (2002), vol. 56, no. 5-6, page 208
		- EIHOLZER ET AL., EUR. J. PEDIATRICS, (1998), vol. 157, no. 5, pages 368 - 377
		- ROSS ET AL., J. BIOL. CHEM., (1996), vol. 271, no. 36, pages 21696 - 21977
		- KATAKAM ET AL., J. CONTROLLED RELEASE, (1997), vol. 49, no. 1, pages 21 - 26
		- HERBERGER ET AL., PROC. INTL. SYMP. CONTROLLED RELEASE OF BIOACTIVE MATERIALS, (1996), vol. 23, pages 835 - 836
		- KIM ET AL., INTL. J. PHARMACEUTICS, (2001), vol. 229, no. 1-2, pages 107 - 116
		- HARO ET AL., J. CHROMATOGRAPHY B, (1998), vol. 720, pages 39 - 47
		- BENNANI-BAITI ET AL., GENOMICS, (1995), vol. 29, pages 647 - 652
		- WU ET AL., J. CHROMATOGRAPHY, (1990), vol. 500, pages 595 - 606

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p